The GOLPH3 Knockout SK-HEP-1 Polyclonal Cells consist of a polyclonal population of SK-HEP-1 human hepatic adenocarcinoma cells engineered with CRISPR/Cas9-mediated disruption of the GOLPH3 gene. In contrast to monoclonal isolates, the polyclonal composition captures a broader spectrum of knockout-induced phenotypic variation, enhancing the robustness of functional studies. This knockout model provides a loss-of-function system to study GOLPH3-dependent cellular processes, eliminating potential clonal bias through a heterogeneous pool.
The SK-HEP-1 cell line, derived from the ascites of a patient with liver adenocarcinoma, is a well-established model for hepatocellular carcinoma (HCC). These epithelial-like cells retain key characteristics of hepatic tumor cells, including anchorage-independent growth and tumorigenicity in vivo, and are extensively utilized to explore hepatocarcinogenesis, drug sensitivity, and metastatic mechanisms, making them an ideal platform for GOLPH3 knockout analysis.
GOLPH3 encodes a Golgi-associated phosphoprotein central to vesicle trafficking, Golgi architecture, and secretion. It functions downstream of PI3K/AKT signaling, activated by AKT kinase-mediated phosphorylation. GOLPH3 interacts with MYO18A to form a complex that tethers Golgi membranes to the actin cytoskeleton, facilitating Golgi dispersal. It also binds DNA-PK, influencing the DNA damage response, and promotes mTOR activation via the AKT-mTOR axis, coupling growth signals to anabolic metabolism and cell survival.
In hepatocellular carcinoma, GOLPH3 overexpression drives oncogenic signaling, enhancing mTOR activity, proliferation, and resistance to therapeutics. Disrupting GOLPH3 in SK-HEP-1 cells allows dissection of its roles in HCC tumorigenesis, drug resistance, and cell migration. Loss of GOLPH3 may sensitize cells to DNA-damaging agents and mTOR inhibitors, providing a platform to study therapeutic vulnerabilities. Beyond liver cancer, this model is relevant to breast, lung, and prostate malignancies where GOLPH3 contributes to tumor progression.
Applications include investigating Golgi biology, signal transduction, and tumor cell behavior using assays such as western blotting, immunofluorescence, proliferation, migration, colony formation, and drug sensitivity testing. These polyclonal knockout cells are suited for functional genomics, target validation, and mechanistic studies. For additional information, validation data, or pricing, please contact Ascent Research.
